Data Insights

ABL-001 by Compass Therapeutics for Metastatic Biliary Tract Cancer: Likelihood of Approval

ABL-001 is under clinical development by Compass Therapeutics and currently in Phase III for Metastatic Biliary Tract Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - ABL-001 in Metastatic Biliary Tract Cancer

Data Insights

CTX-471 by Compass Therapeutics for Head And Neck Cancer: Likelihood of Approval

CTX-471 is under clinical development by Compass Therapeutics and currently in Phase I for Head And Neck Cancer. According to...

Data Insights

CTX-8371 by Compass Therapeutics for Oral Cavity (Mouth) Cancer: Likelihood of Approval

CTX-8371 is under clinical development by Compass Therapeutics and currently in Phase I for Oral Cavity (Mouth) Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-8371 in Oral Cavity (Mouth) Cancer

Data Insights

CTX-8371 by Compass Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

CTX-8371 is under clinical development by Compass Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-8371 in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

CTX-8371 by Compass Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

CTX-8371 is under clinical development by Compass Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-8371 in Triple-Negative Breast Cancer (TNBC)

Data Insights

CTX-8371 by Compass Therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

CTX-8371 is under clinical development by Compass Therapeutics and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-8371 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

CTX-8371 by Compass Therapeutics for Metastatic Melanoma: Likelihood of Approval

CTX-8371 is under clinical development by Compass Therapeutics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-8371 in Metastatic Melanoma

Data Insights

CTX-8371 by Compass Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

CTX-8371 is under clinical development by Compass Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-8371 in Non-Small Cell Lung Cancer

Data Insights

CTX-8371 by Compass Therapeutics for Hypopharyngeal Cancer: Likelihood of Approval

CTX-8371 is under clinical development by Compass Therapeutics and currently in Phase I for Hypopharyngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-8371 in Hypopharyngeal Cancer

Data Insights

CTX-8371 by Compass Therapeutics for Laryngeal Cancer: Likelihood of Approval

CTX-8371 is under clinical development by Compass Therapeutics and currently in Phase I for Laryngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-8371 in Laryngeal Cancer

Data Insights

CTX-8371 by Compass Therapeutics for Oropharyngeal Cancer: Likelihood of Approval

CTX-8371 is under clinical development by Compass Therapeutics and currently in Phase I for Oropharyngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CTX-8371 in Oropharyngeal Cancer